Design, synthesis, in vitro inhibition and toxicological evaluation of human carbonic anhydrases I, II and IX inhibitors in 5-nitroimidazole series

J Enzyme Inhib Med Chem. 2020 Dec;35(1):109-117. doi: 10.1080/14756366.2019.1685510.

Abstract

With the aim to obtain novel compounds possessing both strong affinity against human carbonic anhydrases and low toxicity, we synthesised novel thiourea and sulphonamide derivatives 3, 4 and 10, and studied their in vitro inhibitory properties against human CA I, CA II and CA IX. We also evaluated the toxicity of these compounds using zebrafish larvae. Among the three compounds, derivative 4 showed efficient inhibition against hCA II (KI = 58.6 nM). Compound 10 showed moderate inhibition against hCA II (KI = 199.2 nM) and hCA IX (KI = 147.3 nM), whereas it inhibited hCA I less weakly at micromolar concentrations (KI = 6428.4 nM). All other inhibition constants for these compounds were in the submicromolar range. The toxicity evaluation studies showed no adverse effects on the zebrafish larvae. Our study suggests that these compounds are suitable for further preclinical characterisation as potential inhibitors of hCA I, II and IX.

Keywords: Carbonic anhydrases; carbonic anhydrase inhibitors; lethal concentration; synthesis; toxicity evaluation; zebrafish embryos.

MeSH terms

  • Animals
  • Carbonic Anhydrase I / antagonists & inhibitors*
  • Carbonic Anhydrase I / metabolism
  • Carbonic Anhydrase II / antagonists & inhibitors*
  • Carbonic Anhydrase II / metabolism
  • Carbonic Anhydrase IV / antagonists & inhibitors*
  • Carbonic Anhydrase IV / metabolism
  • Carbonic Anhydrase Inhibitors / chemical synthesis
  • Carbonic Anhydrase Inhibitors / chemistry
  • Carbonic Anhydrase Inhibitors / pharmacology*
  • Dose-Response Relationship, Drug
  • Humans
  • Larva / drug effects
  • Molecular Structure
  • Nitroimidazoles / chemical synthesis
  • Nitroimidazoles / chemistry
  • Nitroimidazoles / pharmacology*
  • Structure-Activity Relationship
  • Zebrafish

Substances

  • Carbonic Anhydrase Inhibitors
  • Nitroimidazoles
  • Carbonic Anhydrase I
  • Carbonic Anhydrase II
  • Carbonic Anhydrase IV
  • CA2 protein, human
  • CA4 protein, human
  • 4-nitroimidazole

Grants and funding

The work was supported by grants from Sigrid Jusélius Foundation (SP, MP), Finnish Cultural Foundation (HB, AA), Academy of Finland (SP), and Jane & Aatos Erkko Foundation (SP). Authors acknowledge financial support from ERC advanced grant (ERC-ADG-2015, no. 694812 – Hypoximmuno).